import centered from './centered/manifest.json'; import choice from './choice/manifest.json'; import { globalManifests } from './global'; import modal from './modal/manifest.json'; import choicePage from './pages/choice.json'; import description from './pages/description.json'; import modalPage from './pages/modal.json'; import progress from './pages/progress.json'; import { idOf, mergeManifests } from './schema'; import split from './split/manifest.json'; import stacked from './stacked/manifest.json'; /** * Properties live in JSON beside their page so a tool outside the plugin reads * the same file the plugin does, rather than a second copy that drifts. * * Labels sit there untranslated on purpose: nothing in the flow renders them, * and a string in JSON cannot reach make-pot anyway. */ export const descriptionManifests = () => [centered, split]; export const progressManifests = () => [stacked]; export const choiceManifests = () => [choice]; export const modalManifests = () => [modal]; const everyTemplate = () => [ ...descriptionManifests(), ...progressManifests(), ...choiceManifests(), ...modalManifests(), ]; const PAGE_OF = { centered: 'description', split: 'description', stacked: 'progress', choice: 'choice', modal: 'modal', }; export const pageManifests = () => [ description, progress, choicePage, modalPage, ]; const pageManifest = (page) => pageManifests().find((entry) => idOf(entry) === page); /** * Global, then the page, then the template. Nothing reads this at runtime — a * page reads its variables from the cascade — so it exists for a tool that has * to know what it may set, and for the contract test over the three levels. */ export const resolvedFor = (template) => { const page = pageManifest(PAGE_OF[template]); const own = everyTemplate().find((entry) => idOf(entry) === template); return mergeManifests([ ...globalManifests(), ...(page ? [page] : []), ...(own ? [own] : []), ]); };

Restore backup mode is enabled so most options are disabled.
If you want to activate these options to change the migration website you need to restart the installer and deactivate the Restore backup mode option

Pharmacy Board recalls Medfill (MEBENDAZOLE 100mg) from the Sierra Leone Market due to alleged bleeding and death. -

Pharmacy Board recalls Medfill (MEBENDAZOLE 100mg) from the Sierra Leone Market due to alleged bleeding and death.

By /

Pharmacy Board Recalls Medfil Mebendazole 100mg

By Ndeamoh Mansaray & Tamba Tengbeh

Sierra Eye Salone on Monday 28th November ,2022 posted on ,” Pharmacy Board recalls Medfill (MEBENDAZOLE 100mg) from the Sierra Leone Market due to alleged bleeding and death. They are currently supervising the quarantine of the said product so that no patient will have access to it pending the conclusion of the ongoing investigation.”

Responding to the story, the Outreach Coordinator of the Sierra Leone Pharmacy Board, Mambu Ibrahim Kamara confirmed that the Recall of MedFil (MEBENDAZOLE 100mg) from the Sierra Leone Market due to alleged Bleeding and Death story was “true”

He noted that the Pharmacy Board received a Suspected Adverse Drug Reaction report of bleeding and death allegedly linked to Mebfil (Mebendazole 100mg) last week.

“The reason board has started an investigation and requested the Marketing Authorization Holder (MAH) to recall all Mebfil products from the Sierra Leone market, including all distribution points such as hospitals, wholesalers, pharmacies, drug stores, and patent medicine shops,” Kamara averred.

The Board currently supervising the quarantine of the said product so that no patient or consumer will have access to it pending the conclusion of the ongoing investigation according to the Outreach Coordinator.

Kamara added that in the press release on 28th November 2022, the board has called on all healthcare professionals not prescribe Mebfil to patients and the general public to dispense and not to take Mebfil until the investigation is completed and a formal communication is released by the Pharmacy Board of Sierra Leone, Ministry of Health and Sanitation.

Pharmacy Board of Sierra Leone (PBSL) is mandated to ensure that manufacturer’ representatives or marketing authorization holders (MAH) have a functional pharmacovigilance system in place so that they can assume responsibility and liability for their products on the market and to ensure that appropriate actions are taken when necessary. The manufacturer representative or MAH should ensure that all information that is important to the benefit-risk ratio of a product is reported promptly to PBSL in accordance with PBSL’s PV regulatory obligations.

Scroll to Top